Summit Therapeutics (SMMT) Assets Average (2020 - 2026)

Summit Therapeutics' Assets Average history runs 7 years deep, the most recent figure standing at $699.5 million for Q1 2026.

• Quarterly Assets Average rose 70.74% year-over-year to $699.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $699.5 million (up 70.74% YoY) and the FY2025 annual result came in at $593.4 million, up 85.86% from the prior year.
• Assets Average was $699.5 million for Q1 2026 at Summit Therapeutics, up from $506.5 million in the prior quarter.
• Across five years, Assets Average topped out at $699.5 million in Q1 2026 and bottomed at $106.1 million in Q2 2022.
• A 5-year average of $323.8 million and a median of $292.9 million in 2025 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2023 — Assets Average surged 299.86% — and 2024, when it slumped 58.68%.
• Summit Therapeutics' Assets Average stood at $409.7 million in 2022, then slumped by 48.58% to $210.7 million in 2023, then soared by 122.68% to $469.2 million in 2024, then grew by 7.94% to $506.5 million in 2025, then surged by 38.12% to $699.5 million in 2026.
• Business Quant data shows SMMT's Assets Average at $699.5 million in Q1 2026, $506.5 million in Q4 2025, and $292.9 million in Q3 2025.